What role do angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), sodium-glucose cotransporter 2 (SGLT2) inhibitors, non-steroidal MRAs, and GLP-1 receptor agonist play in your treatment decisions for patients with CKD in patients with T2D and other comorbidities?
How do you prioritize and sequence therapies for patients with CKD?

This segment explores the operational challenges of implementing the modern quadruple therapy framework for chronic kidney disease, particularly in the overlap of type 2 diabetes and CKM syndrome. Dr. Kushner highlights a common clinical pitfall: the failure to titrate RAS inhibitors to their maximum tolerated doses, noting that sub-therapeutic dosing significantly limits the potential to slow disease progression. To improve adherence, the experts suggest a practical communication shift—explicitly labeling prescriptions with the medication's purpose (e.g., "for slowing kidney disease progression") to help patients understand the systemic protection these drugs provide beyond mere symptom management.

The experts also emphasize the necessity of evolving care models to include pharmacists and mid-level providers who can focus on the intensive work of dose optimization and navigating insurance access barriers. Dr. Beavers introduces the concept of "de-prescribing" less effective medications to reduce pill burden and make the core guideline-directed medical therapy (GDMT) more tolerable for the patient. By combining motivational interviewing with shared decision-making, the panel argues that clinicians can align these complex therapeutic regimens with the patient’s personal health goals, ultimately moving toward a more sustainable and effective management strategy.

The next episode in this series, ‘Tailoring CKD Management to Cardiovascular Risk and Multidisciplinary Monitoring,’ features the experts advancing their conversation on chronic kidney disease. The panelists apply foundational principles from heart failure management to CKD, emphasizing that early "upstream" combination therapy—starting low-to-intermediate doses of multiple drug classes simultaneously—is more effective than slow, sequential titration. They suggest that long-term adherence can be improved by reframing these treatments as a unified regimen that simultaneously targets weight, glycemia, and cardiorenal protection.